Robert Paarlberg is Principal of Paarlberg & Associates LLC, a consultancy specializing in regulatory policy, regulatory intelligence and global clinical trial disclosure strategy and operations. Prior to founding Paarlberg & Associates LLC, Bob worked at Pharmacia (Upjohn) and UCB. Bob is former Chair of DIA’s Clinical Trial Disclosure Community. Bob has more than 40 years of pharmaceutical industry experience with the vast majority of his experience in US and international regulatory affairs. Bob has been active in the clinical trial disclosure and transparency space since 2005.

Suzanne Carlson MA, MFA is President of ABSD Associates LLC. She is an independent medical writing consultant with 12 years of exclusive specialization in clinical trial disclosure and transparency for pharmaceutical companies throughout the United States. Her expertise encompasses both advisory and operational support, including disclosure program audits, onsite training, process development and improvement, and preparing study results and registration records for clinical trial registries. Suzanne’s prior consulting roles include regulatory writer, global competitive intelligence analyst, continuing medical education program editor, and scientific supervisor for international advisory boards and medical symposia.

Kelly is the Director of Clinical Trial Transparency and Disclosure at Pfizer where she provides strategic and operational expertise to support the disclosure of clinical regulatory documents pertaining to Pfizer-sponsored interventional trials on public websites.

Patrick holds a BS in Biology from Penn State University. His clinical research work experience includes data monitoring, regulatory affairs and clinical trial disclosure. Patrick contributed to developing the ClinicalTrials.gov reporting program for the NCI-Designated UPMC Hillman Cancer Center. Since April 2017, he has held a newly created position with the University of Pittsburgh, to develop and manage a program of education and compliance monitoring related to ClinicalTrials.gov.

Merete Joergensen holds an MSc in Statistics and an MBA in Management of Technology. She has more than 30 years of experience in Clinical Research. From 2004 she has been building up the area of Clinical Trials Disclosure in Novo Nordisk A/S. She is now working as independent Clinical trials transparency expert. Prior she headed up Biostatistics in Novo Nordisk A/S for 15 years and worked 7 years as a Clinical Statistician at the medical faculty at Copenhagen University. Further she has served as Clinical Trials Transparency pillar lead, under the Clinical Research Expert Group in EFPIA.

Francine Lane is the VP of Global Transparency at TrialScope and the Chair of the DIA Clinical Trial Disclosure Community. In her day job, Francine is responsible for helping TrialScope customers meet and exceed current disclosure expectations globally, giving them the tools they need to meet all the requirements in this evolving industry. Francine also dedicates her time building relationships with external stakeholders – including sponsors, investigators, regulators, and transparency and patient advocates – to help align the goals and expectations of these groups, as well as help identify more consistent ways sponsors can meet industry standards. Prior to her current role, Francine served as Director of Product Management at TrialScope.

Deborah Collyar is founder and president of Patient Advocates in Research (PAIR), “where research meets reality.” Her leadership in patient engagement and advocacy started in the 1990s after her first cancer diagnosis. She applies business leadership, IT, communication and strategic skills to bridge gaps between scientists, medical providers, payers, governments, and patients. Deborah has vast research experience in translational, clinical, epidemiology, health outcomes, and health delivery fields while working with academia, federal agencies, companies, non-profits, and patient communities. Key patient insights are delivered throughout development, clinical trials, results reporting, data-sharing, standards, genomics, and into practice.

Tab Hoda is a Senior Manager at Amgen and manages the Clinical Trials Disclosure team. She brings years of industry experience including in data management and as a site coordinator. Tab is a foreign medical graduate with an M.B.B.S degree.

Sudip S. Parikh, PhD, serves as Senior Vice President and Managing Director for DIA Americas. He previously served as Vice President and General Manager of Health & Consumer Solutions at Battelle, leading its Healthcare Improvement, Public Health Research, and Consumer, Industrial, and Medical Technology Development teams in R&D supported by government and commercial clients. Dr. Parikh is a board member of Research America, the Friends of Cancer Research, and the Food Innovation Center. He was a Presidential Management Fellow at the National Institutes of Health, and was awarded a National Science Foundation Graduate Research Fellowship while earning his PhD in Macromolecular Structure and Chemistry from The Scripps Research Institute

Donna R. Cryer, JD, has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute, the innovation and collaboration platform for the liver community. For almost a decade Mrs. Cryer led CryerHealth, a healthcare consulting firm she founded, providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision making. She is a frequent speaker on the topic of patient-centeredness and patient engagement in healthcare transformation.

Behtash Bahador is an Associate Director at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into the process of clinical research, and always keeping the needs of patients, participants and the public at the forefront of his work.

Sudipta Chakraborty is a Plain Language Summary Manager at PRA Health Sciences. After earning her PhD in neuroscience from Vanderbilt University, Sudipta joined the medical writing space with the desire to help the public better understand the complexities of science and medicine. Collectively, Sudipta has over 10 years of biomedical communication, with her current specialization in plain language summaries of clinical study results. This has included supporting the operationalization of plain language summaries for sponsors, as well as advising sponsors on plain language best practices and regulatory requirements. Sudipta has also trained and managed other writers in the areas of plain language summary development and management.

Michelle Detry, PhD, is the Director of Adaptive Trial Execution and a Senior Statistical Scientist for Berry Consultants. Dr. Detry’s expertise is in the implementation of adaptive clinical trials, including platform trials. As part of her role in implementing Berry Consultant’s trial designs she is a member of numerous statistical analysis committees that conduct the interim analyses. In addition, she has expertise in clinical trial design, reporting for Data Monitoring Committees, and also serves on Data Monitoring Committees.

Georgina is committed to maximising the benefits from research data and has experience in clinical trials, both in UK academic institutions, and in the field in East Africa. She completed an MSc at the London School of Tropical Medicine and Hygiene and a PhD at University of Glasgow. She then spent 12 months as a postdoctoral researcher in Tanzania, before moving back to the UK and joining the University of Oxford where she worked for 6 years on individual patient data meta analyses. Georgina joined Wellcome in December 2018 and currently leads work on clinical trial transparency and data sharing.

Anthony Keyes, MBA, PMP is the Program Manager, Clinical Research Projects at Johns Hopkins University, Institute for Clinical and Translational Research. As a certified Project Management Professional he has successfully completed several several large-scale research projects. He founded and directs the Johns Hopkins ClinicalTrials.gov Program and Co-chairs the national Clinical Trial Registration and Results Reporting Taskforce. Anthony has over 15 years of experience in many aspects of clinical trial coordination and management. He received his MBA in healthcare management from Johns Hopkins University Carey Business School and a Bachelor's in biology from the University of Maryland, College Park.

Noémie Manent is the Operations Lead in the Clinical Trial Transformation team at the European Medicines Agency, facilitating change management for member states and sponsors with the implementation of the clinical trial Regulation. She has played an essential role in the set up of structured summary results for clinical trials. Also, she has experience in the coordination of inspections for marketing authorisation application. Noemie has more than 15 years experience working in clinical R&D for small and medium enterprises in industry and academia mainly in France and the United Kingdom.

Dr. McNeilly is a Senior Health Policy Analyst with the FDA’s Office of Good Clinical Practice. He is involved in a variety of policy issues related to human subject protections and good clinical practice. He joined FDA in May 2011 with FDA’s Center for Drug Evaluation and Research overseeing compliance programs related to IRBs and RDRCs. Prior to working at FDA, he was the Human Protections Administrator for the Agency for Healthcare Research and Quality. He has also served as a Compliance Oversight Coordinator for the HHS/Office for Human Research Protections. He is a registered pharmacist and trained at the Rutgers University, College of Pharmacy and received his doctoral degree in medicinal chemistry from the University of Maryland.

André Molgat is the Head of Operations for Health Canada's Public Release of Clinical Information initiative. He was previously a core member of the team responsible for the initiative's regulatory and policy development. André has a PhD in biochemistry and post-doctoral training in biochemistry and stem cell biology.

Christopher Pfitzer is the Head of Clinical Trial Transparency Strategy at Biogen where he oversees all plain language and disclosure activities. Chris earned his Master’s degree from NC State University and a Bachelor’s degree from the University of Alabama at Birmingham. Prior to joining pharma, Chris worked extensively with healthcare and nonprofit organizations supporting policy and communications activities.

Liz is Senior Director and Global Public Policy Lead at UCB where she is responsible for establishing the strategic framework, guiding principles, and corporate policies that inform clinical trial transparency and responsible data sharing. She also leads other public policy priorities with a focus on producing sustainable value for people living with severe diseases. Liz led the TransCelerate Clinical Data Transparency Data Anonymization sub-team and co-leads the PhUSE Data Transparency workstream. She is also the UCB representative on the PhRMA Clinical Trials Data Transparency work group. Prior to her role in Data Transparency, Liz has more than 20 years’ experience working as a biostatistician, and has an MSc in Applied Statistics.

Ms. Spears is a 20-year breast cancer survivor and cancer research advocate. Ms. Spears has extensive clinical trial advocacy experience serving as an advocate on the Translational Breast Cancer Research Consortium (TBCRC) and the NCI Breast Cancer Steering Committee (BCSC). She is also Associate Group Chair for Advocacy of the Alliance for Clinical Trials in Oncology (NCTN) as well as Chair of the Alliance Patient Advocate Committee. She is a member of NCI Core Correlative Science Committee (CCSC) and an FDA Patient Representative. She is also an advocate research grant reviewer ASCO (YIA). Ms. Spears is currently working as a scientific research manager and patient advocate at UNC Chapel Hill.

Michael DiMaio is an associate in the health care group at Ropes & Gray. He advises health care providers, pharmaceutical and medical device manufacturers, contract research organizations, and other health care organizations regarding a broad range of privacy, regulatory, compliance, and transactional issues.

Julie Holtzople is a seasoned Clinical Trial Transparency professional. She spent 10 years building Clinical Transparency and Data Sharing at AstraZeneca, becoming an expert in Plain Language Summaries, Clinical Document Anonymization and Clinical Data Sharing. She also led the implementation and readiness for EU CTR Transparency requirements. Julie has been an active member of numerous CTT working groups and organizations contributing to CTT standards and best practices. Prior to AstraZeneca, she started her career as a management consultant working at Ernst & Young and then Booz Allen. Julie has recently returned to consulting as an independent. She specializes in Clinical Trial Transparency, process optimization and program delivery.

Pamela Miller has been with the editorial office of the New England Journal of Medicine for over 20 years, currently serving as Assistant to the Editor. Prior to that she was the General Manager of Margun and GunMar Music and has been a grants administrator at various Boston Hospitals. In her role at the NEJM she manages large projects, including implementing online peer review, overseeing the publication’s 200th Anniversary and digitizing the journal archive. She also implements policy for the editorial office, most recently the ICMJE's requirements around data sharing statements.

Catina O’Leary, PhD, is President and CEO at Health Literacy Media (HLM), a St. Louis based nonprofit that develops and distributes health literate and accessible health and science communications with a wide range of global partners. Before joining HLM in 2012, Catina was Assistant Professor at Washington University School of Medicine. She currently serves as a member of the National Academies of Sciences, Engineering, and Medicine’s Roundtable on Health Literacy, as the Secretary General of the International Health Literacy Association, and on the Board of Rankin Jordan Pediatric Bridge Hospital.

Dr. Oladayo Oyelola is Senior Director and Head, Clinical Trial Information Disclosure at Daiichi Sankyo. He oversees corporate clinical trial transparency/data sharing strategies and compliance activities; coordinates internal disclosure operations’ training, process improvements and trial transparency policy intelligence.He holds a PhD in Clinical Chemistry from Obafemi Awolowo Univ. Ile-Ife, Nigeria, 1990 and received The Rockefeller Foundation Postdoctoral Fellowship, 1991 and National Mentor Role Model Award of Minority Access Inc/Office of Minority Health, NIH, 2001. Dr. Oyelola has over 35 years’ experience in biomedical R&D, and certifications by National Registry of Certified Chemists and American Society for Clinical Pathologists

Thomas Wicks is an experienced strategic leader with over 20 years in life sciences. As Head of Transparency Operations at Citeline, he spearheads strategy for TrialScope's industry-leading disclosure solutions. Thomas is an established thought leader, having spoken at over 60 conferences and authored over 40 publications on disclosure requirements and transparency trends. Thomas is motivated by empowering teams to accelerate solutions that honor trial participants through transparency.

Diane Lehman Wilson has worked in the Office of Regulatory Affairs at the University of Michigan Medical School for nearly a decade. She covers a range of regulatory matters supporting research faculty including clinical trials disclosure, human subjects protection, and FDA inspections of clinical trials. Her earlier career included legal and educational positions, teaching in contexts ranging from pre-school Science, a decade of teaching middle school human rights, English, and History in Detroit, to Continuing Legal Education in areas related to Medicare and Medicaid. She has presented to national audiences on clinical trial disclosure obligations as well as the Clostridium Difficile risks of antibiotics.

Deborah A. Zarin, M.D. was the Director of ClinicalTrials.gov between 2005 and 2018. In that capacity, she oversaw the world’s largest clinical trials registry, as well as the development and implementation of the first public database for summary clinical trial results. She also played a major role in the development and implementation of regulations under FDAAA (42 CFR Part 11) and the NIH trial reporting policy. Dr Zarin’s recent research has been on the quality of trial reporting, as well as issues in the design and analysis of clinical trials. Dr. Zarin has recently joined the MRCT Center as Program Director, Advancing the Clinical Trials Enterprise, and Member of Faculty, Harvard Medical School.

Matthias Zerm is a Lead Expert Clinical Trial Disclosure and R&D Processes at Merz Therapeutics located in Frankfurt/Germany. In this role he coordinates and oversees all clinical trial disclosure activities including registration and results submissions. He is also involved in a wide range of organizational and process-related projects at Merz Therapeutics, such as preparing for the EU-CTR. He is a biologist by training and has >15 years of global experience in the clinical research arena.

Brendan Barnes joined EFPIA in 2002 to work on the alignment of national laws in new member states during the enlargement of 2004. Subsequently, he has been involved in EFPIA’s work on multilateral trade and intellectual property issues, including the EU’s legislation on product diversion and compulsory licensing and on issues relating to access to medicines. More recently, he has been involved in the development of new business models in the areas of neglected disease and infection and is now mainly focused on data governance issues. He previously worked in the pharmaceutical industry for 11 years, in a range of roles including Finance, Strategic Planning and Public Affairs,

Till Bruckner is the founder of TranspariMED, a UK-based initiative that works to end evidence distortion in medicine worldwide. TranspariMED has driven improvements in the posting of clinical trial summary results by combining research with coalition building, advocacy and media outreach, with a particular focus on non-profit trial sponsors. Notably, TranspariMED has been a central participant in the UK House of Commons enquiry into unreported clinical trials and its aftermath. Prior to setting up TranspariMED, Till Bruckner worked for the AllTrials campaign and Transparency International.

Cathal Gallagher is the Associate Director of Clinical Transparency & Trial Disclosure at Regeneron, with over a decade of experience in clinical trial data technology. Specialising in data and document transparency, Cathal develops and implements technical solutions to ensure compliance with EMA Policy 0070 and Health Canada’s PRCI. Known for his strategic approach and dedication to regulatory compliance, he advocates for transparency as a cornerstone of ethical research. Cathal’s interests include blockchain technology, fitness, and continuous self-improvement.

Rebecca Williams, PharmD, MPH, is a Clinical Trials Subject Matter Expert with Essex, Part of Emmes Group. In this role she supports strategic policy and data initiatives with the National Cancer Institute’s Coordinating Center for Clinical Trials. Prior to this role she was the Acting Director of ClinicalTrials.gov at the National Library of Medicine (NLM) after having served as the Assistant Director for over a decade. She has also worked in regulatory and policy aspects of prescription drug advertising and promotion at the Food and Drug Administration and as a consultant. She received her Pharm.D. from the University of Wisconsin-Madison and MPH from Johns Hopkins Bloomberg School of Public Health.

Rebecca Li, PhD, is the Executive Director of Vivli and on faculty at the Center for Bioethics at the Harvard Medical School. Previous to her current role she was the Executive Director of the MRCT Center of Brigham and Women’s Hospital and Harvard for over 5 years and remains a Senior Advisor at the Center. She has over 25 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. She completed a Fellowship in 2013 in the Division of Medical Ethics at Harvard Medical School. She earned her PhD in Chemical and Biomolecular Engineering from Johns Hopkins University.

Lucy Mosquera has a background in biology and mathematics, having done her studies at Queen's University in Kingston and the University of British Columbia. In the past she has provided data management support to clinical trials and observational studies at Kingston General Hospital. She also worked on clinical trial data sharing methods based on homomorphic encryption and secret sharing protocols with various companies. At Replica Analytics, Lucy is responsible for integrating her subject area expertise in health data into innovative methods for synthetic data generation and the assessment of that data, as well as overseeing our analytics program.

Olivia is a senior director of Science and Regulatory Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA). Olivia has extensive multi-disciplinary program management and regulatory policy experience in the biopharmaceutical and biodefense industries, ranging from pre-clinical product development to commercial tech transfer to global supply chain management. She currently leads PhRMA’s global quality and manufacturing, supply chain, and data transparency regulatory advocacy programs.

With more than 27 years of experience in private practice and government, Ms. Walsh helps pharmaceutical and medical device companies comply with, and defend against, FDA regulation. She regularly counsels clients on managing FDA inspections, and responding to seizure and injunction actions, warning letters, and recalls. She has specific expertise in matters involving health care fraud, off-label promotion, and manufacturing practices, and has investigated and negotiated dozens of matters that have implicated False Claims Act liability and exclusion by the HHS Office of Inspector General.

Pooja Phogat brings a unique breadth of operational experience, global leadership, and technical expertise establishing Kinapse as a global market leader in Clinical Trial Disclosure. Currently, Pooja is leading Development Operations group, where she is responsible for Clinical Trial Disclosure and Medical Writing services. She has over 18 years of experience in the Life Sciences Industry with 13 years in disclosure. Pooja’s career started in pharmaceutical industry as a Ph.D in Microbiology and thereafter moving to industry. Pooja is recognized externally as a global thought leader in disclosure with a comprehensive knowledge of disclosure regulations such as FDAAA, Final Rule EU-CTR, Health Canada PRCI and others).

Nirpal Singh Virdee is the Director of Client Services, Technology at Synchrogenix, a Certara company. Nirpal is accountable for business development, client management and consulting for their technology enabled services. Nirpal provides industry insight, market trends and service line alignment when Synchrogenix look to invest, plan and implement new technologies. This includes the adoption of open APIs, real time data, and machine learning within our regulatory services. Nirpal comes with over 21 years of Life Sciences experience. He has an MSc from Brunel University in London. He is considered an industry thought leader, having globally presented at conferences. He has sat on industry advisory panels and publishes articles and Podcasts